Why We Dose Intrathecally episode artwork

EPISODE · Jul 10, 2024 · 29 MIN

Why We Dose Intrathecally

from Patient Empowerment Program: A Rare Disease Podcast

The affected organs of our patients determine the route of administration for an ASO, as certain routes can better target specific organs and offer the best potency. The central nervous system (CNS) is the most common target we encounter, and for this, we dose intrathecally. Let’s dive into how this is done and the particulars of why this approach is used. The Human Body and Barriers The Four Tubes – Enteral, Respiratory, Urinary, and the Central Nervous System (CNS) tube How The Body Constructs Barriers What is Cerebrospinal Fluid (CSF) The Blood-Brain Barrier (BBB) The Types of Molecules That Are Admitted to and Excluded From the CNS Intrathecal Administration of Drugs Outwitting the Blood-Brain Barrier Survey Link – Patient Empowerment Program Podcast: https://forms.office.com/r/1ik9WNs7QB Register for the 2024 Nano-rare Patient Colloquium: https://www.nlorem.org/nano-rare-patient-colloquium-2024/

Episode metadata supplied by the publisher feed · Published Jul 10, 2024

Embed this episode

Ready to play

Why We Dose Intrathecally

0:00 29:18

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Patient Empowerment Program: A Rare Disease Podcast?

This episode is 29 minutes long.

When was this Patient Empowerment Program: A Rare Disease Podcast episode published?

This episode was published on July 10, 2024.

Can I download this Patient Empowerment Program: A Rare Disease Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!